Tema Oncology ETF
CANC
NASDAQ Global Market- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Tema Oncology ETF (CANC) is an actively managed exchange-traded fund that provides targeted exposure to global companies involved in oncology innovation, cancer treatments, and therapies; it invests in a portfolio of approximately 53 equity holdings, including leading firms such as Revolution Medicines, Eli Lilly and Company, Genmab, Roche Holding AG, and Novartis AG, selected through a bottom-up research process emphasizing pioneering companies at attractive valuations. The ETF focuses exclusively on the oncology sector within the biotechnology and healthcare industries, targeting investors seeking pure-play exposure to cancer-related advancements amid rising global demand driven by increasing cancer incidence rates. Launched on August 14, 2023, and managed by Dr. David K. Song, MD, PhD, CFA, CANC trades on the Nasdaq and is issued by Tema ETF Trust under the advisory of Tema ETFs LLC, a New York-based active ETF manager founded in 2023 with headquarters at Brookfield Place, 200 Vesey Street. CANC operates with a global mandate, holding equities from issuers worldwide and concentrating assets in the biotechnology industry, which subjects it to sector-specific risks such as patent expirations, regulatory hurdles, technological obsolescence, and product liability concerns. Tema ETFs backs the fund as part of its platform offering thematic ETFs across life sciences, strategic equity, and alternatives, supported by prominent venture investors including Index Ventures and Accel Partners. The firm serves institutional investors, registered investment advisors, wirehouses, and family offices through tax-aware, actively managed strategies. In a significant recent milestone, CANC surpassed $100 million in assets under management (AUM) in late 2025, just two years after inception, fueled by a year-to-date performance of approximately +48% that outperformed the S&P 500 (+15.7%) and ranked it among the top three healthcare/biotech ETFs; this growth reflects strong institutional adoption and highlights the ETF's positioning as the world's only dedicated pure-play oncology fund. Tema ETFs as a whole achieved over $1 billion in total AUM earlier in 2025, driven by launches including the S&P 500 Historical Weight ETF (DSPY) and Electrification ETF (VOLT), alongside key hires such as Devan O'Dowd as Head of Distribution; however, the firm also announced the liquidation of two underperforming ETFs in July 2025, set to complete by August 1, signaling ongoing portfolio optimization. No major acquisitions, partnerships, or funding rounds specific to CANC were reported in the last 1-2 years, though Tema continues to expand its thematic offerings amid robust oncology sector momentum.